| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 4.4MM | -78% |
| Operating Income | -12.1MM | -587% |
| Operating Expenses | 16.6MM | -6% |
| Net Income | -1.8MM | -270% |
| R&D | 12.3MM | +1% |
| G&A | 4.3MM | +12% |
| Amortization | 200K | -50% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Key Insights Significant control over Harpoon Therapeutics by retail investors implies that the general public has more...
It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually.
Merck (MRK) offers to acquire Harpoon for $680 million. J&J (JNJ) is set to acquire Ambrx Biopharma for approximately $2.0 billion
Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.
(Bloomberg) -- Merck & Co. has agreed to acquire cancer drugmaker Harpoon Therapeutics Inc. for $680 million as it seeks to solidify its leadership position in the profitable oncology space.Most Read from BloombergChinese Billionaire Is Second-Biggest Foreign Owner of US LandIPhone Survives 16,000-Foot Fall, Helps Steer Jet-Panel HuntBoeing Slumps After Panel Blowout Leads to Partial 737 GroundingMusk’s Drug Use Concerns Tesla, SpaceX Leaders, WSJ SaysEmirates’ Clark Says Blowout Illustrates Boe
Cancer-focused biotech companies Ambrx and Harpoon snapped up a pair of takeover deals. AMAM stock and HARP stock soared.
Boeing slumps after the FAA orders the temporary grounding of 737 MAX 9 planes after a jet operated by Alaska Airlines lost a section of its fuselage midair, while shares of Spirit Aerosystems, the supplier responsible for installing the emergency-door configuration involved in Friday’s incident, fall sharply.
Merck (MRK) is set to acquire Harpoon Therapeutics (HARP) in a deal valued at $680 million. Twilio (TWLO) Co-Founder Jeff Lawson steps down as CEO amid pressures from activist investor groups. Lastly, shares of footwear brand Crocs (CROX) have soared by over 20% on Monday after updating its guidance and full-year revenue forecasts for 2023. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by...
(Bloomberg) -- More than $6.4 billion in health-care deals were announced on Monday as the annual JPMorgan Healthcare Conference kicked off in San Francisco. Most Read from BloombergBoeing Slumps After Panel Blowout Leads to Partial 737 GroundingMusk’s Drug Use Concerns Tesla, SpaceX Leaders, WSJ SaysChina Says It Caught Foreign Consultant Spying for UK’s MI6The deals include Merck & Co.’s $680 million purchase of cancer drugmaker Harpoon Therapeutics Inc., Boston Scientific Corp.’s $3.7 billion
Cancellations mounted at the airline after one of its jets suffered a blowout that left a gaping hole in the side of the fuselage. Merck is buying the drug developer for about $680 million. Johnson & Johnson is buying the drug developer for about $2 billion.